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INTRODUCTION
In patients with chronic liver diseases, determination of the degree of liver fi brosis and the presence of cirrhosis has important implications for prognostic, therapeutic, and monitoring purposes. Although liver biopsy currently remains the gold standard in the assessment of liver fi brosis, it has associated risks of morbidity and, less commonly, mortality ( 1 ) . Th ere has been a rapid increase in the development of non-invasive methods to assess liver fi brosis. Measuring liver stiff ness using transient elastography has recently become available for research and clinical practice to assess liver fi brosis and cirrhosis. Th e majority of the early validating studies have been performed in patients with chronic hepatitis C in the Western population. Subsequent validation studies with other liver diseases further support its usefulness ( 2 -5 ) . However, compared with hepatitis C, there are still relatively limited data on liver stiff ness in chronic hepatitis B.
Th e rationale for transient elastography is based on the theory that liver stiff ness is positively correlated with the amount of fi brotic Liver stiffness measurement using transient elastography has become a popular tool to assess liver fi brosis. The aim of this study was to determine liver stiffness values and histological features in healthy subjects and in patients with chronic hepatitis B (CHB).
METHODS:
A total of 157 people were included (28 healthy subjects and 18 patients with occult hepatitis B infection, 102 with active CHB, and 9 with end-stage hepatitis B cirrhosis). Histology and liver stiffness measurements were obtained from all patients.
RESULTS:
The median liver stiffness in healthy subjects and in occult hepatitis B, active hepatitis B, and end-stage cirrhosis patients was 4.6, 4.2, 8.7, and 33.8 kPa, respectively. In healthy subjects and in patients with occult hepatitis B infection, none had signifi cant fi brosis on histology, and all had liver stiffness < 7.2 kPa. In patients with active CHB, 32 (31 % ) had liver stiffness >11.0 kPa, but only four (12 % ) had cirrhosis on histology. Using liver stiffness to predict cirrhosis in this group had a sensitivity of 100 % , a specifi city of 69 % , a positive predictive value of 10 % , and a negative predictive value of 100 % . All nine patients with end-stage liver cirrhosis had liver stiffness >11.0 kPa. The overall area under the ROC curve (AUROC) for diagnosing cirrhosis using a cutoff of 11.3 kPa was 0.89.
tissue within the liver. In a study of 429 healthy subjects without known liver diseases, the mean liver stiff ness measurement was reported to be 5.49 ± 1.59 kPa ( 6 ) . For patients with chronic liver disease, higher liver stiff ness measurements are observed with increasing level of fi brosis, with higher liver stiff ness cutoff values corresponding to increasing stages of fi brosis. In patients with cirrhosis, the optimal cutoff values used for patients with cirrhosis can range from 11.0 to 25.3 kPa, depending on the underlying liver disease ( 2,4,7 -9 ) . It is well established that the cutoff liver stiff ness values used for diff erent fi brosis stages are dependent on the underlying disease. However, there is increasing evidence to suggest that even within the same disease, the optimal cutoff values for diff erent degrees of fi brosis may vary with the underlying infl ammatory activity, as refl ected by higher levels of serum alanine aminotransferase (ALT) ( 10 ) . In patients with chronic hepatitis B (CHB), the infl ammatory activity and its surrogate marker, ALT level, can fl uctuate during the course of the disease. Several recent studies have shown that underlying infl ammatory activity can increase liver stiff ness values, causing an overestimation of the degree of fi brosis ( 11 -13 ) .
In this study, we determined liver stiff ness values and histological features in subjects with no known liver disease, occult hepatitis B infection, active CHB, and hepatitis B-related cirrhosis, and compared the diff erences among these four groups of subjects.
METHODS
Th is study recruited a total of 187 subjects from Queen Mary Hospital, University of Hong Kong, Hong Kong, between November 2005 and November 2008. Th ere were four groups of subjects (28 healthy subjects, 18 occult hepatitis B patients, 121 active CHB patients, and 20 end-stage cirrhosis patients). Th e group without known underlying liver disease (healthy subjects) was living-related donors recruited from the liver transplant program at Queen Mary Hospital. Subjects in this group were negative for hepatitis B surface antigen, antibody to hepatitis C virus, significant alcohol intake history (as defi ned by an intake of >20 g / day), or any other known liver diseases. Patients with occult hepatitis B infection were recruited from healthy blood donors who were negative for hepatitis B surface antigen, but positive for hepatitis B core antibody with detectable hepatitis B virus (HBV) DNA (method described below). Patients with active CHB were recruited from the hepatitis clinic at Queen Mary Hospital. Th ese patients were positive for hepatitis B surface antigen for over 6 months, with elevated ALT and HBV DNA levels >20,000 IU / ml. Th e hepatitis B-related cirrhosis group was liver transplant recipients recruited from the liver transplant program. Written and verbal consent was obtained for liver biopsy and liver stiff ness measurements, respectively. Th is study has been approved by the institutional review board of the University of Hong Kong.
Liver histology
All patients included in this study had liver histology available. Liver biopsy was performed on the patient groups with occult hepatitis B and active CHB using a 17-G Menghini needle (Hepafi x, B.Braun Melsungen AG, Germany) aft er written informed consent. Th e liver histology was graded using the modifi ed hepatic activity index score ( 14, 15 ) . In the groups with normal subjects and HBVrelated cirrhosis, histology was obtained at the time of liver transplantation from the donor (intra-operative biopsy specimen) and from the recipient (explant specimen).
Liver stiffness measurements
Liver stiff ness was measured using transient elastography (Fibroscan, Echosens, Paris, France). All patients had transient elastography performed either on the same day or within 1 week of obtaining the liver histology. Th e procedure has been well described in earlier studies ( 2, 5 ) . Patients who had a success rate of < 50 % , interquartile range-to-liver stiff ness ratio of >30 % , or < 10 validated measurements, were excluded. Liver stiff ness scores were expressed as the median value of the validated measurements in units of kilopascals (kPa).
Liver biochemistry and viral load
Complete blood count, coagulation profi le, and routine liver biochemistry were determined at the time of liver biopsy or surgery. In patients with active CHB, the HBV DNA levels were determined using the Cobas Taqman assay, with a lower limit detection of 12 IU / ml (Roche Diagnostics, Branchburg, NJ). For detection of occult hepatitis B in blood donors, HBV DNA was extracted from 500 μ l of serum using the QIAamp DSP Virus Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer ' s instructions, with a fi nal elution of 26 μ l. HBV DNA in the extracts was then quantitatively measured by the Artus HBV RG PCR Kit (Qiagen Hamburg GmbH, Hamburg, Germany), using the Rotor-Gene 3000 real-time multiplexing system (Corbett Research, Mortlake, Australia), according to the manufacturer ' s instructions. Th is test has a 95 % lower limit of quantitation of 3.8 IU / ml of serum and a linear range of detection from 1.1 to 4 × 10 9 IU / ml of serum. As the serum HBV DNA levels of these occult HBV subjects were very low, to eliminate the chance of false positive or negative results, Artus HBV test was performed thrice. Genuine HBV DNA-positive result was defi ned as having ≥ 2 out of 3 positive HBV DNA signals by three independent Artus test runs.
Statistical analysis
All statistical analyses were performed using the SPSS version 14.0 (SPSS, Chicago, IL). Continuous variables with skewed distribution were analyzed using Mann -Whitney test. Related data were analyzed using the Wilcoxon ' s paired test. Continuous variables with more than two independent samples were analyzed using the Kruskal -Wallis test. Correlation between liver stiff ness and liver biochemistry and histology score was performed using Spearman ' s bivariate correlation. Multivariate analysis was performed using multiple regressions on variables that were signifi cant on univariate analysis. Th e receiver-operating characteristic (ROC) curves and area under ROC (AUROC) were calculated. Th e optimal cutoff values were defi ned as the value giving the highest sensitivity and specifi city. A P value of < 0.05 was considered statistically signifi cant. 
RESULTS
A total of 187 patients had both liver biopsy and transient elastography performed during the study period. Of these, thirty (16 % ) patients were excluded because of suboptimal liver stiffness measurements. Of these suboptimal measurements, 11 patients were liver recipients with very small livers and ascites, accounting for the overall higher-than-expected failure rate of liver stiff ness measurements. Th e remaining 19 patients were excluded because of suboptimal measurements secondary to overlying adipose tissue. In all, 157 patients were included in the fi nal analysis. Th e demographics and laboratory data are summarized in Table 1 .
Healthy subjects
A total of 28 liver donors were recruited as healthy subjects, with a median age of 32 years (range 18 -56) and ALT of 16 U / l (range 4 -51). None of the healthy subjects had fi brosis on liver histology. Th e median liver stiff ness was 4.6 kPa (range 2.0 -7.1). In all, 26 (93 % ) subjects had liver stiff ness of < 6.0 kPa. All healthy subjects had liver stiff ness values of < 7.2 kPa, the optimal cutoff for F2 as defi ned in a previous study of CHB patients ( 7 ).
Occult hepatitis B
A total of 18 patients with evidence of occult hepatitis B infection were included, with a median age of 47 years (range 20 -59) and ALT of 24 U / l (range 8 -48); 14 (78 % ) patients had no fi brosis on liver biopsy and the remaining four (22 % ) patients had minimal stage 1 fi brosis. Th e median liver stiff ness in patients with occult hepatitis B was 4.2 kPa (range 3.4 -6.9), with all patients having liver stiff ness values of < 7.2 kPa.
Active chronic hepatitis B
In all, 102 patients had active CHB, with a median age of 41 years (range 18 -63). Th e median ALT was 89 U / l (range 46 -501). Th e median liver stiff ness was 8.7 kPa (range 3.6 -44.3). Th irty-two (31 % ) patients had liver stiff ness value >11.0 kPa, the optimal cutoff value for cirrhosis defi ned in a previous study of CHB patients ( 7 ) . Of these 32 patients, 12 (38 % ) had minimal fi brosis (stage 0 -1), and a further 16 (50 % ) patients had moderate fi brosis (stage 2 -3). Th e remaining four (12 % ) patients had histological cirrhosis with hepatic activity index fi brosis stage 5 -6. In active CHB, using liver stiff ness measurements to predict cirrhosis had a sensitivity of 100 % , a specifi city of 69 % , a positive predictive value of 10 % , and a negative predictive value of 100 % .
Of these 102 patients with chronic active hepatitis B, 15 patients underwent repeat liver biopsies with valid liver stiff ness measurements at 12 months aft er commencing oral antiviral therapy with subsequent normalization of ALT. None of these patients had cirrhosis at either the fi rst or second biopsy. However, three patients had liver stiff ness measurement of >11.0 kPa, indicating cirrhosis before treatment. Of these three patients, two had liver stiff ness of < 11.0 kPa (8.5 and 6.8 kPa) aft er 1 year of antiviral therapy with normalization of ALT. Th ere was a signifi cant decline in liver stiffness aft er ALT normalization compared with the time of active hepatitis (8.6 vs. 6.0 kPa, P = 0.001) without associated signifi cant decline in fi brosis stages.
End-stage chronic hepatitis B cirrhosis
A total of nine patients had end-stage liver cirrhosis secondary to CHB requiring liver transplantation. Th e median age was 55 years (range 51 -59), with a median liver stiff ness of 33.8 kPa (range 11.9 -75.0) and ALT of 91 U / l (range 16 -324). All these patients had liver stiff ness value of >11.0 kPa, the cutoff for cirrhosis in CHB patients ( 7 ).
Comparison of groups
Th e demographic and laboratory data of the four diff erent groups are shown in Table 2 . Th e liver stiff ness value of the study population is summarized in Figure 1 according to their groups. Th ere was no signifi cant diff erence in median liver stiff ness between healthy subjects and occult hepatitis B (4.6 vs. 4.2 kPa, respectively, P = 0.796). Patients with active CHB had a signifi cantly higher median liver stiff ness compared with occult hepatitis B patients (8.7 vs. 4.2 kPa, respectively, P < 0.001) and healthy subjects (8.7 vs. 4.6 kPa, respectively, P < 0.001). In patients with minimal (F1) fi brosis in the occult hepatitis B and active CHB groups, there was a trend for higher liver stiff ness measurement in the active CHB group (5.2 vs. 7.0 kPa, respectively, P = 0.066). Patients with end-stage CHB cirrhosis had a signifi cantly higher median liver stiff ness compared with active CHB patients (33.8 vs. 8.7 kPa, respectively, P < 0.001), occult hepatitis B patients (33.8 vs. 4.2 kPa, respectively, P < 0.001), and healthy subjects (33.8 vs. 4.6 kPa, respectively, P < 0.001).
Relationship between liver stiffness and biological parameters
Th e correlation between liver stiff ness and biological parameters is shown in Table 3 . Th ere were signifi cant correlations with age, necro-infl ammatory activity, histological fi brosis, bilirubin, alkaline phosphatase, ALT, aspartate aminotransferase (AST), γ -glutamyl transferase, platelets, and international normalized ratio. Aft er stratifi cation into diff erent age groups and levels of ALT and platelets, there were higher liver stiff ness measurements 
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Liver Stiffness in Hepatitis B and Healthy Subjects in patients with higher age groups, higher ALT levels, and lower platelet counts ( Table 4 ) . Aft er multivariate analysis, histological fi brosis, ALT, aspartate aminotransferase, γ -glutamyl transferase, and platelets remained signifi cantly correlated with liver stiff ness.
Diagnostic performance
Th e AUROC, optimal cutoff s, sensitivity, and specifi city for diagnosing stage 2, 3, and ≥ 4 fi brosis for our study population is shown in Table 5 . Th e ROC curves for stage 2, 3, and ≥ 4 fi brosis are shown in Figure 2 .
DISCUSSION
Transient elastography has been used increasingly as a noninvasive method for assessing liver fibrosis. There have been many validating studies performed to date in patients with various underlying liver diseases, including chronic hepatitis C, primary biliary disease, alcoholic liver disease, fatty liver respectively ( 16 ) . Although earlier studies did not show any signifi cant eff ect of underlying infl ammatory activity on liver stiffness values, more recent studies have shown that in severe fl ares of hepatitis, liver stiff ness may be spuriously elevated ( 11 -13 ) . At present, there are less reports regarding liver stiff ness on CHB as the technology was developed in Europe where hepatitis C is more common. Th erefore, most of the earlier studies were performed on patients with chronic hepatitis C. In the current study, we determined the liver stiff ness of healthy subjects and patients at diff erent ends of the spectrum of hepatitis B-related diseases ranging from occult infection to end-stage cirrhosis. Although the diagnostic accuracy of transient elastography appeared excellent with an AUROC of 0.89 for stage 3 and 4 fi brosis, the performance was dependent on the underlying disease activity. In both healthy subjects and occult hepatitis B patients (none had histological grade of F2, F3, or F4 fi brosis), all subjects had liver stiff ness values of < 7.1 kPa. Th ere were no false-positive liver stiff ness results indicating advance fi brosis or cirrhosis. Th is suggests that liver stiff ness of < 7.1 kPa can be safely adopted as defi ning insignifi cant fi brosis. In patients with end-stage hepatitis B cirrhosis, there were no falsenegative results with transient elastography, with all subjects having liver stiff ness values of >11.0 kPa.
In patients with active CHB, the diagnostic accuracy of transient elastography appeared to be dichotomous. It had an excellent negative predictive value of 100 % in excluding cirrhosis. However, transient elastography had a poor positive predictive value of 10 % in active CHB; 28 out of 32 patients with liver stiff ness >11.0 kPa had no evidence of cirrhosis on histology. Th erefore, in active CHB, additional tests such as liver biopsy or serum markers of fi brosis are required to confi rm the presence of severe fi brosis or cirrhosis in patients with liver stiff ness >11.0 kPa.
Although previous studies have shown that severe necro-infl ammatory activity (as defi ned by ALT >1,000) can aff ect liver stiff ness, this study suggests that a much lesser degree of infl ammation may also increase liver stiff ness, and therefore reduce the accuracy of transient elastography ( 11, 12 ) . Th ese results are also in accordance with a previous large population study that had shown that even milder degrees of ALT elevation are associated with signifi cantly higher median values of liver stiff ness ( 17 ) .
In the present study, a cutoff level of liver stiff ness of 11.3 kPa for cirrhosis is associated with high sensitivity and specifi city (93 and 82 % , respectively) for the overall group. Th is is in accordance with another validating study of CHB patients in which the sensitivity and specifi city for diagnosing cirrhosis using a cutoff of 11.0 kPa were 93 and 87 % , respectively ( 7 ) . Th e low positive predictive value of 11.0 kPa in the present study for the group with active hepatitis can be explained by the diff erent population studied. Th e median ALT of the current study was higher than that of the previous study (89 vs. 54 U / l, respectively). In addition, aft er multivariate analysis, both ALT and aspartate aminotransferase were signifi cantly associated with liver stiff ness in addition to histological fi brosis and platelet levels, whereas only histological fi brosis and platelet levels were signifi cantly associated with liver stiff ness in the previous validation study. A recent study on CHB patients has also shown that patients with disease, and CHB ( 2, 4, 5, 8, 9 ) . A recent meta-analysis on the diagnostic performance of transient elastography has also been published showing an AUROC of 0.89 and 0.94 for F3 and F4, the same fi brosis stage, albeit higher ALT levels, tend to have higher liver stiff ness values, and the diagnostic performance of transient elastography is reduced ( 10 ) . It emphasizes the role of abnormal ALT on liver stiff ness measurement. Transient elastography remains one of the most promising noninvasive techniques in assessing liver fi brosis. As this technology matures with increasing experience, we are now beginning to understand the fi ner intricacies of measuring liver stiff ness. Th is study shows that liver stiff ness measurement is not accurate in diagnosing cirrhosis in patients with active hepatitis and elevated ALT using the current cutoff values. Unfortunately, these patients are also a group in which clinicians are very interested to know whether underlying advance fi brosis or cirrhosis is present, so that the decision to start antiviral therapy can be made. To increase the diagnostic accuracy of transient elastography, the optimal timing of performing a scan needs to be established, that is, whether it should be performed (or repeated) aft er ALT is normalized. An alternative approach would be to adopt diff erent cutoff values depending on the ALT, or to combine liver stiff ness values into a more complex model, including markers of infl ammation, to improve the diagnostic accuracy.
One limitation of this study was that even though the study had a wide spectrum of disease severity, further useful information can be gained with the availability of patients with inactive CHB, and with the inclusion of more patients with well-compensated cirrhosis. Nevertheless, this study was able to show the performance of transient elastography in a wide range of disease severity. Furthermore, this study provides histological correlation with liver stiff ness for the fi rst time in healthy patients and in patients with occult hepatitis B. Th e median liver stiff ness in healthy subjects in this study was similar to the mean level of liver stiff ness in an earlier study of healthy subjects without histological correlation (4.6 and 5.5 kPa, respectively) ( 6 ) . Another limitation of this study is that the body weight and body mass index was not measured, which may aff ect the liver stiff ness measurements.
In conclusion, liver stiff ness measurement has an overall good diagnostic accuracy, particularly with an excellent negative predictive value in patients with CHB. However, in patients with active hepatitis and elevated ALT, measuring liver stiff ness has a poor positive predictive value, and further studies are required to determine both the optimal timing for performing transient elastography, and the optimal cutoff values for diff erent levels of infl ammatory activity.
